Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Glass vials for liquid samples

AstraZeneca, with their extensive world-wide development and manufacturing capabilities, have been able to have the vaccine approved and licenced for use in over 170 countries, with over 20 manufacturing sites across the world, including the Serum Institute of India, working together to release the one billion doses worldwide.

As the manufacturing of adenovirus vector vaccines is complex and requires significant investment in infrastructure and expertise to ensure the safety and quality of the vaccine, we are working together with AstraZeneca to ensure that significant technology transfer happens between the global manufacturing sites and their supply chains.

Read the full story on the University of Oxford website